RxDoctor Payments Data

Michael Koontz, MD

Internal Medicine · Monterey, CANPI 1245410588

Payments from drug & device makers

$1,836,791in general payments, 2019–2025

Across 179 payments — averaging $10,261 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.4M
  • Genentech, Inc.$213K
  • Seagen Inc.$109K
  • Daiichi Sankyo Inc.$66K
  • Eli Lilly$64K
  • Takeda Pharmaceuticals U.S.A., Inc.$10K
  • plus $8K from 16 others
$4,902in research payments, 2019–2025

Across 3 payments — averaging $1633.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$5K

What the payments were for

  • Food & beverage$55198%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,836,791 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$4,888,992
Medicare patients
1,086
Services billed
235,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax13$133,601
CalquenceAcalabrutinib Maleate11$130,225
ProcritEpoetin Alfa22$69,596
Everolimus15$25,972
Abiraterone Acetate44$25,234
Imatinib Mesylate20$16,481
EliquisApixaban20$12,775
Ondansetron Hcl21$505
Gabapentin19$504
Prednisone77$393
Dexamethasone21$338
Levothyroxine Sodium27$304
Ondansetron OdtOndansetron12$198
Omeprazole16$182
Prochlorperazine Maleate11$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonProcrit$20$69,59622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Monterey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →